Tokyo, March 12 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060895) titled 'Low doses of L-DOPA and CPZ therapy for obsessive compulsive disorder' on March 12.
Study Type:
Interventional
Study Design:
Basic Design - Single arm
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Uncontrolled
Primary Sponsor:
Institute - Osaka Neurological Institute
Condition:
Condition - obsessive compulsive disorder
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To investigate the efficacy and safety of chlorpromazine (CPZ) and LDOPA for the psychiatric symptoms of obsessive-compulsive disorder (OCD).
Basic objectives2 - Safety,Efficacy
Intervention:
Interventions/Control_1 - LDOPA 150 mg and chlorpromazine 15 mg were administered to patients with obsessive-compulsive disorder.
Eligibility:
Age-lower limit - 18
years-old
=
Gender - Male and Female
Key inclusion criteria - 1) Patients diagnosed with OCD according to DSM-5 and with a YBOCS score of 16 or higher.
2) Patients who have provided written consent to participate in the study.
3) Patients whose medications have not changed for at least three months.
Key exclusion criteria - Nothing in particular
Target Size - 9
Recruitment Status:
Recruitment status - Completed
Date of protocol fixation - 2024 Year 05 Month 22 Day
Date of IRB - 2024 Year 05 Month 22 Day
Anticipated trial start date - 2024 Year 06 Month 23 Day
Last follow-up date - 2027 Year 06 Month 22 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069667
Disclaimer: Curated by HT Syndication.
